ʻIke ʻia ka haʻawina hou i ka maʻi maʻi maʻi umauma maʻi honua

i kakauia ma hoʻoponopono

Ke piʻi aʻe nei nā hihia maʻi maʻi, e like me kahi noiʻi hou e hoʻohālikelike ana i ka helu o ka maʻi kanesa ma ka honua holoʻokoʻa ma 2010 a me 2019. Ma waena o nā ʻikepili, ua ʻike nā mea noiʻi ua piʻi ka nui o ka maʻi kanesa o ka honua ma +26% a ʻo ka maʻi maʻi umauma ke kumu nui o ka maʻi kanesa. ʻO nā makahiki ola i hoʻololi ʻia e pili ana i ke kīnā (DALYs), nā make, a me nā makahiki o ke ola i nalowale (YLLs) ma waena o nā wahine ma ka honua ma 2019.

Hoʻolapala, PDF & Email

Wahi a Research and Markets, ke manaʻo nei ka mākeke lāʻau lapaʻau maʻi umauma honua e ulu i $ 19.49 biliona e 2025 ma kahi CAGR o 7.1%. Ma waena o nā mea hoʻomohala biotech e hana ana i 2022 ma nā lāʻau lapaʻau hou no ka maʻi kanesa o ka umauma ʻo Oncolytics Biotech Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, a me AstraZeneca PLC.

Ma waena o nā maʻi maʻi i manaʻo ʻia e Oncolytics Biotech Inc. a me kāna ʻoihana immunotherapeutic agent pelareorep, ʻo ka maʻi maʻi umauma ka manaʻo nui o ka ʻoihana, e like me kāna leka hou loa i nā mea kuleana i loiloi i kāna mau hana i 2021 a wehewehe i kāna papahana 2022 e hiki mai ana.

I loko o kāna papahana maʻi maʻi maʻi umauma a hiki i kēia manawa, ua ʻike ʻo Oncolytics i ka ʻoi aku o ka pālua o ke ola holoʻokoʻa i ka metastatic HR+/HER2- nā maʻi maʻi maʻi maʻi umauma i mālama ʻia me ka pelareorep ma IND-213-e like me ka ʻike ʻia mai nā hopena noiʻi i hāʻawi ʻia ma 2017.

Ma hope o ka nānā ʻana i ka ʻikepili hou aʻe, ua koho ʻo Oncolytics e kālele i ʻekolu mau pahuhopu hiki ke hoʻokō ʻia e nā regulators a me nā hoa lāʻau lapaʻau o ka hui, e hōʻike ana i nā hana koʻikoʻi i kahi noiʻi hoʻopaʻa inoa. Aia kēia: 1. E hōʻoia ana e hana ana ka pelareorep ma o ka hana immunotherapeutic; 2. E hoʻoholo ana inā hui pū ʻia ka pelareorep me nā mea hoʻopaneʻe hoʻopaʻa kino; a me 3. ʻO ka ʻike ʻana i kahi biomarker e koho i nā maʻi e loaʻa paha nā hopena lapaʻau maikaʻi aʻe.

Ma ʻApelila 2021, ua hōʻike ʻo Oncolytics i ka ʻikepili cohort mai kāna haʻawina AWARE-1, e alakaʻi ʻia ana me Roche Holding AG (OTC: RHHBY), e hōʻike ana ua hoʻokō ka hui i nā pahuhopu mua ʻelua i kuhikuhi ʻia ma luna.

Ma hope o Dekemaba i ka 2021 San Antonio Breast Cancer Symposium (SABCS), ua hōʻike ʻo Oncolytics i kahi hōʻano palekana maikaʻi mai kāna IRENE Phase 2 Triple-Negative Breast Cancer Trial e loiloi ana i ka palekana a me ka pono o ka pelareorep i hui pū ʻia me ka anti-PD-1 checkpoint inhibitor. retifanlimab mai Incyte Corporation no ka lapaʻau ʻelua a ʻekolu paha o nā maʻi me ka metastatic triple-negative breast cancer (TNBC).

Ua hōʻike ʻia nā ʻikepili palekana mai ka hoʻāʻo ʻana i ka hui pū ʻana, ʻaʻohe pilikia palekana i ʻike ʻia i kekahi o nā maʻi i kākau ʻia i ka hoʻokolokolo i ka manawa o ka hōʻike.

Ke hoʻomau nei ka haʻawina IRENE a e hoʻomau i ke kākau inoa ʻana i nā mea maʻi ma ka Rutgers Cancer Institute o New Jersey a me ka Ohio State University Comprehensive Cancer Center.

Ua hāʻawi hou aku ʻo Incyte Corporation i kahi mea hou e pili ana i kāna retifanlimab i hui pū ʻia me BriaCell Therapeutics' alakaʻi moho lapaʻau Bria-IMTTM ma SABCS. I hōʻuluʻulu ʻia i ka mea hou, ʻoi aku ka kiʻekiʻe o ke ola holoʻokoʻa i ka poʻe maʻi i ka hoʻopaʻa ʻana i ka hui ʻana, e hōʻike ana i kahi hopena additive a synergistic a kākoʻo i ka hoʻomau ʻana o ke aʻo ʻana. Wahi a ka pūnaewele o BriaCell, manaʻo ʻia ka ʻikepili palekana a me ka pono a hiki i 2022.

Ua komo koke ʻo Pfizer, Inc. i kahi hui hoʻokolohua lapaʻau a hāʻawi aku i ka ʻaelike me Celcuity, kahi e hāʻawi ai ke kanaka nunui lāʻau lapaʻau iā Palbociclib (Ibrance) no ka hoʻohana ʻana i kahi haʻawina hoʻokolohua 3 e mālama ʻia e Celcuity me ke kumu kūʻai ʻole i ka hui.

Manaʻo ʻia ka hoʻāʻo ʻana o ka pae 3 i ka hapa mua o 2022 e loiloi ana i ka hoʻohana ʻana i ka pan-PI3K/mTOR inhibitor gedatolisib (PF-05212384) i hui pū ʻia me ka palbociclib a me ka fulvestrant no nā maʻi me ka estrogen receptor (ER)-positive, HER2 -negative advanced breast cancer. E hoʻokuʻu ʻo Celcuity i nā kikoʻī hou aʻe e pili ana i ka hoʻokolohua lapaʻau ma hope o ka haʻi ʻōlelo a me nā pane mai ka FDA.

Ma ka hopena o 2021, ua hoʻolaha ʻo AstraZeneca PLC a me nā hoa ʻo Daiichi Sankyo ua hōʻoia ka European Medicines Agency (EMA) i kāna Type II Variation Application no trastuzumab deruxtecan (T-DXd; Enhertu) no ka mālama ʻana i ka umauma HER2 maikaʻi. nā maʻi maʻi ʻaʻai.

I kēia manawa, ʻo ka mea maʻi mua me HR +, HER2- inoperable metastatic breast cancer i hoʻopaʻa ʻia me ka datopotamab deruxtecan (DS-1062a; dato-DXd) ma ke ʻano he māhele 3 TROPION-Breast01 hoʻāʻo (NCT05104866). ʻO ka TROP2-directed DXd ADC e hoʻomohala ʻia nei e Daiichi Sankyo a me AstraZeneca i kēia manawa i ka hoʻokolokolo ʻana ma ka honua, randomized, open-label trial ma kahi maʻa o 6 mg/kg vs ke koho ʻana o ka mea noiʻi no ka chemotherapy.

ʻO kekahi ala ʻē aʻe e hoʻomaikaʻi ai i nā manawa i ka hakakā ʻana i ka maʻi kanesa, ʻo ia ka heihei e hoʻomaikaʻi i ka ʻike mua. Wahi a ka Carol Milgard Breast Center ʻo ka ʻike mua ke kī.

Ua kiki ʻo Roche Holding AG i $290 miliona i loko o kahi pōʻai kālā i ʻoi aku ma mua o $ 1 biliona i loko o nā mea hoʻomohala biopsy wai Freenome. 

Hoʻolapala, PDF & Email

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

eTurboNews | Nūhou TravelIndustry